{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:32:40Z","timestamp":1790728360141,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T00:00:00Z","timestamp":1483833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib has demonstrated significant activity in relapsed\/refractory mantle cell lymphoma (MCL) in clinical trials. However, the impact of hematopoietic cell transplantation on the outcomes of ibrutinib and the predictive factors for ibrutinib response has not been well studied. Hence, we conducted a multicenter retrospective study of MCL patients who received ibrutinib to (1) determine the overall response rate (ORR), duration of response (DOR), progression\u2010free survival (PFS), and overall survival (OS) of ibrutinib in routine clinical practice, (2) examine characteristics predictive of response to ibrutinib therapy, and (3) describe the outcomes of patients failing ibrutinib. Ninety\u2010seven patients met the eligibility criteria. Overall response rate and median DOR to ibrutinib were 65% and 17\u00a0months, respectively. Only lack of primary refractory disease was predictive of ibrutinib response on multivariate analysis. Twenty\u2010nine patients received postibrutinib therapies, with an ORR of 48% and a median DOR of 3\u00a0months. The median OS and PFS for the entire group (n\u00a0=\u00a097) was 22 and 15\u00a0months, respectively. On multivariate analysis, ibrutinib response, low MCL international prognostic index, and absence of primary refractory disease were predictors of better PFS, while ibrutinib response and Eastern Cooperative Oncology Group performance status \u22641 were predictors of better OS. The median OS postibrutinib failure was 2.5\u00a0months. Our results confirm the high ORR and DOR of ibrutinib in MCL and that prior hematopoietic cell transplantation does not negatively influence ibrutinib outcomes. Survival following ibrutinib failure is poor with no specific subsequent therapy showing superior activity in this setting. As a result, for select (transplant eligible) patients, allogeneic transplant should be strongly considered soon after ibrutinib response is documented to provide durable responses.<\/jats:p>","DOI":"10.1002\/hon.2380","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T04:06:44Z","timestamp":1483934804000},"page":"528-535","source":"Crossref","is-referenced-by-count":64,"title":["Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study"],"prefix":"10.1002","volume":"35","author":[{"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine  St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang W.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Oak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine  St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology West Virginia University  Morgantown WV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Calzada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute Emory University  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute Emory University  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Farmer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Levine Cancer Institute\/Carolinas HealthCare System  Charlotte NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Levine Cancer Institute\/Carolinas HealthCare System  Charlotte NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tallarico","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Chicago  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Chicago  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation and Cell Therapy Program University of Alabama  Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Wisconsin  Madison WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran N.","family":"Hari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2002.30221"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.05.001"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.56"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.01.009"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3435"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V124.21.78.78","article-title":"Mutational analysis of patients with primary resistance to single\u2010agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL)","volume":"124","author":"Balasubramanian S","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL 3001 (RAY) trial","volume":"34","author":"Lenz G","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:58:57Z","timestamp":1695488337000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/hon.2380"],"URL":"https:\/\/doi.org\/10.1002\/hon.2380","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,8]]}}}